Hyperuricaemia: a marker of increased cardiovascular risk in rheumatic patients: analysis of the ACT-CVD cohort

Table 2 Univariate associations between CV risk variables and prospective CV events in GA and non-GA patients

	GA (172)			Non-GA(686)
	Event-free (154)	Event (18)	p (event vs. none)	Event-free (640)	Event (46)	p (event vs. none)
Tertiles serum uric acid (% 1^st/2^nd/3^rd)	37.3/32.0/30.7	33.3/16.7/50.0	0.208	40.6/28.3/31.2	15.9/25.0/59.1	0.000*
Uric acid lowering therapy, %	74.0	66.7	0.504	0	0	n.a.
Allopurinol, %	64.3	66.7	0.842	0	0	n.a.
Sex, % male	91.6	72.2	0.011*	24.8	37.0	0.069*
Age, mean, years	58.5	68.8	0.000*	58.6	64.9	0.001*
Systolic blood pressure, mean, mmHg	152.0	143.0	0.092*	143.9	152.1	0.015*
Antihypertensive therapy, %	34.4	77.8	0.000*	26.3	45.7	0.004*
Smoking, %	26.0	11.1	0.147*	22.0	23.9	0.767
TC/HDL ratio, mean	4.83	4.71	0.623	3.74	3.95	0.265
Total cholesterol, mean	5.38	4.83	0.037*	5.38	5.19	0.234
HDL cholesterol, mean	1.18	1.05	0.104*	1.53	1.40	0.057*
Statin therapy, %	11.7	22.2	0.205	8.0	15.2	0.088*
Diabetes, %	5.8	11.1	0.387	6.4	6.5	0.975
GlyHb, mean, %Hb	5.83	6.58	0.004*	5.83	5.91	0.408
BMI, mean, kg/m²	30.1	32.9	0.017*	27.4	28.8	0.058*
MDRD, mean, ml/min	83.5	58.1	0.002*	89.7	83.2	0.091*
NT proBNP, mean, nmol/L	14.5	230.9	0.083*	14.1	45.4	0.005*
hsCRP, mean, g/l	5.76	9.44	0.238	5.90	7.21	0.390
Corticosteroids, %	0.0	0.0	-	10.0	10.9	0.850

GA: gouty arthritis; hsCRP: high sensitivity C-reactive protein; TC: Total cholesterol; HDL: high density lipoprotein; GlyHb: glycated haemoglobin; BMI: body mass index; MDRD: modification of diet in renal disease; NT proBNP: N-terminal pro-brain natriuretic peptide. *variable included in the respective COX regression analyses.

ISSN: 1471-2474